Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals (NASDAQ: ACAD) announced that its Compensation Committee granted inducement awards to eighteen new employees on February 6, 2025. The awards include non-qualified stock options to purchase 171,065 shares of common stock at $19.13 per share and 55,170 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over four years, with 50% vesting after two years and the remaining 50% in two equal annual installments. Both awards are subject to continued employment with Acadia.
The grants were made under Acadia's 2024 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).
Acadia Pharmaceuticals (NASDAQ: ACAD) ha annunciato che il suo Comitato per la Compensazione ha concesso premi di indennità a diciotto nuovi dipendenti il 6 febbraio 2025. I premi includono opzioni su azioni non qualificate per acquistare 171.065 azioni ordinarie a $19.13 per azione e 55.170 unità di azioni vincolate (RSU).
Le opzioni su azioni matureranno in quattro anni, con il 25% che matura dopo un anno e il restante mensilmente per 36 mesi. Le RSU matureranno in quattro anni, con il 50% che matura dopo due anni e il restante 50% in due rate annuali uguali. Entrambi i premi sono soggetti a un impiego continuativo presso Acadia.
I conferimenti sono stati effettuati nell'ambito del Piano di Indennità 2024 di Acadia e sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4).
Acadia Pharmaceuticals (NASDAQ: ACAD) anunció que su Comité de Compensación otorgó premios de inducción a dieciocho nuevos empleados el 6 de febrero de 2025. Los premios incluyen opciones sobre acciones no calificadas para comprar 171,065 acciones ordinarias a $19.13 por acción y 55,170 unidades de acciones restringidas (RSUs).
Las opciones sobre acciones se adquirirán durante cuatro años, con el 25% adquiriéndose después de un año y el resto mensualmente durante 36 meses. Las RSUs se adquirirán durante cuatro años, con el 50% adquiriéndose después de dos años y el 50% restante en dos pagos anuales iguales. Ambos premios están sujetos a la continuación del empleo en Acadia.
Las concesiones se realizaron bajo el Plan de Inducción 2024 de Acadia y cumplen con la Regla de Cotización 5635(c)(4) de Nasdaq.
아카디아 제약 (NASDAQ: ACAD)는 보상위원회가 2025년 2월 6일에 18명의 신규 직원에게 유인 보상을 부여했다고 발표했습니다. 보상에는 비자격 주식 옵션이 포함되어 있으며, 이는 171,065주를 주당 $19.13에 구매할 수 있는 옵션과 55,170주의 제한 주식 단위 (RSU)가 포함됩니다.
주식 옵션은 4년에 걸쳐 발생하며, 1년 후 25%가 발생하고 나머지는 36개월 동안 매월 발생합니다. RSU는 4년에 걸쳐 발생하며, 2년 후 50%가 발생하고 나머지 50%는 두 번의 동일한 연간 할부로 발생합니다. 두 보상 모두 아카디아에서의 지속적인 고용에 따라 달라집니다.
이 보상은 아카디아의 2024 유인 계획에 따라 이루어졌으며, Nasdaq 상장 규칙 5635(c)(4)에 부합합니다.
Acadia Pharmaceuticals (NASDAQ: ACAD) a annoncé que son Comité de Rémunération avait accordé des primes d'incitation à dix-huit nouveaux employés le 6 février 2025. Les primes comprennent des options d'achat d'actions non qualifiées pour acheter 171 065 actions ordinaires à 19,13 $ par action et 55 170 unités d'actions restreintes (RSU).
Les options d'achat d'actions seront acquises sur une période de quatre ans, avec 25 % acquises après un an et le reste mensuellement sur 36 mois. Les RSU seront acquises sur quatre ans, avec 50 % acquises après deux ans et les 50 % restants en deux versements annuels égaux. Les deux primes sont soumises à un emploi continu chez Acadia.
Les attributions ont été faites dans le cadre du Plan d'Incitation 2024 d'Acadia et sont conformes à la Règle de Cotation Nasdaq 5635(c)(4).
Acadia Pharmaceuticals (NASDAQ: ACAD) gab bekannt, dass der Vergütungsausschuss am 6. Februar 2025 Induktionspreise an achtzehn neue Mitarbeiter vergeben hat. Die Preise umfassen nicht qualifizierte Aktienoptionen zum Kauf von 171.065 Stammaktien zu einem Preis von 19,13 $ pro Aktie und 55.170 eingeschränkten Aktieneinheiten (RSUs).
Die Aktienoptionen werden über vier Jahre fällig, wobei 25% nach einem Jahr fällig werden und der Rest monatlich über 36 Monate. Die RSUs werden über vier Jahre fällig, wobei 50% nach zwei Jahren und die verbleibenden 50% in zwei gleichen jährlichen Raten fällig werden. Beide Auszeichnungen sind an eine fortdauernde Beschäftigung bei Acadia gebunden.
Die Vergaben erfolgten im Rahmen des Induktionsplans 2024 von Acadia und entsprechen der Nasdaq-Listing-Regel 5635(c)(4).
- Expansion of workforce with 18 new employees indicating company growth
- Structured employee retention program through 4-year vesting schedule
- Potential shareholder dilution from new stock options and RSUs
Each stock option has an exercise price per share equal to
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the fore front of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250214260863/en/
Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com
Source: Acadia Pharmaceuticals Inc.
FAQ
How many shares were granted in ACAD's February 2025 inducement awards?
What is the exercise price for ACAD's February 2025 stock option grants?
What is the vesting schedule for ACAD's February 2025 RSU grants?
How do ACAD's February 2025 stock options vest?
